{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:58:35Z","timestamp":1787111915971,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020365","name":"Centers for Disease Control and Prevention Foundation","doi-asserted-by":"publisher","award":["NU17CE924978, NH28CE003556"],"award-info":[{"award-number":["NU17CE924978, NH28CE003556"]}],"id":[{"id":"10.13039\/100020365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020365","name":"Centers for Disease Control and Prevention Foundation","doi-asserted-by":"publisher","award":["NU17CE924978, NH28CE003556"],"award-info":[{"award-number":["NU17CE924978, NH28CE003556"]}],"id":[{"id":"10.13039\/100020365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020365","name":"Centers for Disease Control and Prevention Foundation","doi-asserted-by":"publisher","award":["NU17CE924978, NH28CE003556"],"award-info":[{"award-number":["NU17CE924978, NH28CE003556"]}],"id":[{"id":"10.13039\/100020365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020365","name":"Centers for Disease Control and Prevention Foundation","doi-asserted-by":"publisher","award":["NU17CE924978, NH28CE003556"],"award-info":[{"award-number":["NU17CE924978, NH28CE003556"]}],"id":[{"id":"10.13039\/100020365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020365","name":"Centers for Disease Control and Prevention Foundation","doi-asserted-by":"publisher","award":["NU17CE924978, NH28CE003556"],"award-info":[{"award-number":["NU17CE924978, NH28CE003556"]}],"id":[{"id":"10.13039\/100020365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020365","name":"Centers for Disease Control and Prevention Foundation","doi-asserted-by":"publisher","award":["NU17CE924978, NH28CE003556"],"award-info":[{"award-number":["NU17CE924978, NH28CE003556"]}],"id":[{"id":"10.13039\/100020365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020365","name":"Centers for Disease Control and Prevention Foundation","doi-asserted-by":"publisher","award":["NU17CE924978, NH28CE003556"],"award-info":[{"award-number":["NU17CE924978, NH28CE003556"]}],"id":[{"id":"10.13039\/100020365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-025-01237-5","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T15:11:14Z","timestamp":1749309074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Community-based drug checking at syringe service programs in New York City observe an increasing prevalence of xylazine from 2021 through 2024"],"prefix":"10.1186","volume":"22","author":[{"given":"Leonardo A. Dominguez","family":"Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarelix","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izza","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Trinidad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Helmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Harocopos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"issue":"4","key":"1237_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2885.1988.tb00189.x","volume":"11","author":"SAT Greene","year":"1988","unstructured":"Greene SAT, Xylazine JC. A review of its pharmacology and use in veterinary medicine. J Veterin Pharmacol Therapeut. 1988;11(4):295\u2013313.","journal-title":"J Veterin Pharmacol Therapeut"},{"issue":"3","key":"1237_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/0735-6757(86)90070-7","volume":"4","author":"DG Spoerke","year":"1986","unstructured":"Spoerke DG, Hall AH, Grimes MJ, Honea BN 3rd, Rumack BH. Human overdose with the veterinary tranquilizer xylazine. Am J Emerg Med. 1986;4(3):222\u20134.","journal-title":"Am J Emerg Med"},{"issue":"5","key":"1237_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/jat\/9.5.234","volume":"9","author":"A Poklis","year":"1985","unstructured":"Poklis A, Mackell MA, Case ME. Xylazine in human tissue and fluids in a case of fatal drug abuse. J Anal Toxicol. 1985;9(5):234\u20136.","journal-title":"J Anal Toxicol"},{"issue":"10","key":"1237_CR4","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.7326\/M23-2001","volume":"176","author":"J D'Orazio","year":"2023","unstructured":"D\u2019Orazio J, Nelson L, Perrone J, Wightman R, Haroz R. Xylazine adulteration of the heroin-fentanyl drug supply: a narrative review. Ann Intern Med. 2023;176(10):1370\u20136.","journal-title":"Ann Intern Med"},{"key":"1237_CR5","doi-asserted-by":"crossref","unstructured":"Rodriguez N, Vargas Vidot J, Panelli J, Colon H, Ritchie B, Yamamura Y. GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles. Drug Alcohol Depend. 2008;96(3):290-3.","DOI":"10.1016\/j.drugalcdep.2008.03.005"},{"key":"1237_CR6","doi-asserted-by":"crossref","unstructured":"Spencer MC, Warner M, Garnett MF. Drug overdose deaths involving xylazine: United States, 2018\u20132021. National Center for Health Statistics; 2023. Contract No.: 30.","DOI":"10.15620\/cdc:129519"},{"key":"1237_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109380","volume":"233","author":"J Friedman","year":"2022","unstructured":"Friedman J, Montero F, Bourgois P, Wahbi R, Dye D, Goodman-Meza D, et al. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233: 109380.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1237_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12954-024-00959-2","volume":"21","author":"W Bradford","year":"2024","unstructured":"Bradford W, Figgatt M, Scott KS, Marshall S, Eaton EF, Dye DW. Xylazine co-occurrence with illicit fentanyl is a growing threat in the Deep South: a retrospective study of decedent data. Harm Reduct J. 2024;21(1):46.","journal-title":"Harm Reduct J"},{"issue":"4","key":"1237_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/injuryprev-2020-043968","volume":"27","author":"J Johnson","year":"2021","unstructured":"Johnson J, Pizzicato L, Johnson C, Viner K. Increasing presence of xylazine in heroin and\/or fentanyl deaths, Philadelphia, Pennsylvania, 2010\u20132019. Inj Prev. 2021;27(4):395\u20138.","journal-title":"Inj Prev"},{"key":"1237_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104118","volume":"118","author":"AB Collins","year":"2023","unstructured":"Collins AB, Wightman RS, Macon EC, Guan Y, Shihipar A, Krieger M, et al. Comprehensive testing and rapid dissemination of local drug supply surveillance data in Rhode Island. Int J Drug Policy. 2023;118: 104118.","journal-title":"Int J Drug Policy"},{"key":"1237_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/PHH.0000000000001581","author":"TC Green","year":"2022","unstructured":"Green TC, Olson R, Jarczyk C, Erowid E, Erowid F, Thyssen S, et al. Implementation and uptake of the massachusetts drug supply data stream: a statewide public health-public safety partnership drug checking program. J Public Health Manag Pract. 2022. https:\/\/doi.org\/10.1097\/PHH.0000000000001581.","journal-title":"J Public Health Manag Pract"},{"key":"1237_CR12","unstructured":"Bettigole C, Franklin F, Hom J. Risks of xylazine use and withdrawal in people who use drugs in Philadelphia. Philadelphia Department of Public Health; 2022. Contract No.: PDPH-HAN-00377A-03-16-22."},{"issue":"2","key":"1237_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/PHH.0000000000002061","volume":"31","author":"ER Payne","year":"2025","unstructured":"Payne ER, Thomas GJ, Fallico M, Clear A, Gogia M, Zamboni L. Development, evaluation, and initial findings of new york state department of health community drug checking pilot programs. J Public Health Manag Pract. 2025;31(2):317\u201327.","journal-title":"J Public Health Manag Pract"},{"key":"1237_CR14","unstructured":"Tuazon E, Sun T, Weitz A, Gasdaska B, G C-C, Zaidi I, et al. Unintentional Drug Poisoning (Overdose) Deaths in New York City in 2023. New York City Department of Health and Mental Hygiene; 2024 October 2024. Contract No.: 142."},{"key":"1237_CR15","unstructured":"Tuazon EB, Sun T, Weitz A, DeWalt J, Mantha S, Harocopos A. Unintentional Drug Poisoning (Overdose). Deaths in New York City in 2022. New York City Department of Health and Mental Hygiene; 2023 September 2023. Contract No.: 137."},{"key":"1237_CR16","doi-asserted-by":"crossref","unstructured":"Jiang XC, Sarah, Strahan, Andrea E, Rivera Blanco, Liz, Mikosz, Christina A, Guy Jr, Gery P, Dowell, Deborah. Reported xylazine use among adults aged \u226518 years evaluated for substance use treatment \u2014 United States, July 2022\u2013September 2023. Morbidity and Mortality Weekly Report (MMWR). 2024;73(26):594\u20139.","DOI":"10.15585\/mmwr.mm7326a2"},{"key":"1237_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-024-00940-z","author":"D German","year":"2024","unstructured":"German D, Genberg B, Sugarman O, Saloner B, Sawyer A, Glick JL, et al. Reported xylazine exposure highly associated with overdose outcomes in a rapid community assessment among people who inject drugs in Baltimore. Harm Reduct J. 2024. https:\/\/doi.org\/10.1186\/s12954-024-00940-z.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1237_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/ADM.0000000000001245","volume":"18","author":"R McFadden","year":"2024","unstructured":"McFadden R, Wallace-Keeshen S, Petrillo Straub K, Hosey RA, Neuschatz R, McNulty K, et al. Xylazine-associated wounds: clinical experience from a low-barrier wound care clinic in Philadelphia. J Addict Med. 2024;18(1):9\u201312.","journal-title":"J Addict Med"},{"key":"1237_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-024-01082-y","author":"WH Eger","year":"2024","unstructured":"Eger WH, Plesons M, Bartholomew TS, Bazzi AR, Hauschild MH, McElrath CC, et al. Syringe services program staff and participant perspectives on changing drug consumption behaviors in response to xylazine adulteration. Harm Reduct J. 2024. https:\/\/doi.org\/10.1186\/s12954-024-01082-y.","journal-title":"Harm Reduct J"},{"key":"1237_CR20","unstructured":"New York City Department of Health and Mental Hygiene. 2022 Advisory #33: Xylazine and Fentanyl in the New York City (NYC) Drug Supply. Health Alert Network (HAN)2022."},{"key":"1237_CR21","unstructured":"New York City Department of Health and Mental Hygiene. What Is Xylazine? Online: New York City Department of Health and Mental Hygiene. p. 1\u20132."},{"key":"1237_CR22","unstructured":"Kerr TT, Kenneth. Drug checking as a harm reduction intervention. British Columbia Centre on Substance Use; 2017."},{"issue":"1","key":"1237_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12954-023-00764-3","volume":"20","author":"L Gozdzialski","year":"2023","unstructured":"Gozdzialski L, Wallace B, Hore D. Point-of-care community drug checking technologies: an insider look at the scientific principles and practical considerations. Harm Reduct J. 2023;20(1):39.","journal-title":"Harm Reduct J"},{"key":"1237_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102661","volume":"77","author":"TC Green","year":"2020","unstructured":"Green TC, Park JN, Gilbert M, McKenzie M, Struth E, Lucas R, et al. An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. Int J Drug Policy. 2020;77: 102661.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1237_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.focus.2024.100203","volume":"3","author":"C Delcher","year":"2024","unstructured":"Delcher C, Quesinberry D, Torabi S, Berry S, Keck JW, Rani A, et al. Wastewater Surveillance for Xylazine in Kentucky. AJPM Focus. 2024;3(3): 100203.","journal-title":"AJPM Focus"},{"issue":"1","key":"1237_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12954-022-00727-0","volume":"19","author":"B Wallace","year":"2022","unstructured":"Wallace B, van Roode T, Burek P, Hore D, Pauly B. Everywhere and for everyone: proportionate universalism as a framework for equitable access to community drug checking. Harm Reduct J. 2022;19(1):143.","journal-title":"Harm Reduct J"},{"key":"1237_CR27","doi-asserted-by":"publisher","DOI":"10.2196\/56755","volume":"8","author":"ID Aronson","year":"2024","unstructured":"Aronson ID, Ardouin-Guerrier MA, Baus JE, Bennett AS. Barriers to, and facilitators of, checking drugs for adulterants in the era of fentanyl and xylazine: qualitative study. JMIR Form Res. 2024;8: e56755.","journal-title":"JMIR Form Res"},{"key":"1237_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103741","volume":"106","author":"S Klaire","year":"2022","unstructured":"Klaire S, Janssen RM, Olson K, Bridgeman J, Korol EE, Chu T, et al. Take-home drug checking as a novel harm reduction strategy in British Columbia. Canada Int J Drug Policy. 2022;106: 103741.","journal-title":"Canada Int J Drug Policy"},{"key":"1237_CR29","unstructured":"Quinter AD, DeBord JS, Denn MT, Logan KK, Krotulski AJ. Surveillance Efforts to Track Drug Market Changes in Philadelphia, PA. Online: Center for Forensic Science Research and Education (CFSRE); 2024."},{"issue":"1","key":"1237_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.amepre.2023.08.016","volume":"66","author":"MC Kennedy","year":"2024","unstructured":"Kennedy MC, Dong H, Tobias S, Buxton JA, Lysyshyn M, Tupper KW, et al. Fentanyl concentration in drug checking samples and risk of overdose death in Vancouver. Canada Am J Prev Med. 2024;66(1):10\u20137.","journal-title":"Canada Am J Prev Med"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01237-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01237-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01237-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T15:11:16Z","timestamp":1749309076000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01237-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1237"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01237-5","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was submitted to and approved by the New York City Department of Health and Mental Hygiene Institutional Review Board as a research activity (protocol #21\u2013034).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to participate in the drug checking pilot study and program included information that data collected will be stored and analyzed for scientific purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}